Answers are grounded in this paper and cite their sources.
Systematic review evaluates Hydroxyurea–Imatinib therapy's efficacy and safety in gliomas, suggesting potential benefits.
Despite various treatment approaches, recurrence, high toxicity, and poor survival persist in glioma management. This meta-analysis evaluates the efficacy and safety of biomarker-based Hydroxyurea–Imatinib therapy as a potential therapy.
No takes yet. Share an insight, caveat, or question.
Saif et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: